Artios Pharma

OverviewSuggest Edit

Artios is a leading independent DNA Damage Response (DDR) company focussed on developing first-in-class treatments for cancer. Established in May 2016, the Company is led by an experienced scientific and leadership team with proven expertise in DDR drug discovery. Artios is building a pipeline of next-generation DDR programmes, including through a unique partnership with Cancer Research Technology (CRT), the development and commercialisation arm of Cancer Research UK (CRUK), and with leading DNA repair researchers worldwide. The Company’s investors include SV Life Sciences, Merck Ventures, Imperial Innovations, Arix Bioscience PLC, CRT Pioneer Fund (managed by Sixth Element Capital), and AbbVie Ventures. Artios is based at the Babraham Institute in Cambridge, UK.
TypePrivate
Founded2016
HQCambridgeshire, GB
Websiteartiospharma.com

Latest Updates

Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Artios Pharma

Niall Martin

Niall Martin

Chief Executive Officer
Graeme Smith

Graeme Smith

Chief Scientific Officer
Ian Smith

Ian Smith

Chief Medical Officer
Tania Dimitrova

Tania Dimitrova

Chief Business Officer
Andrew Muncey

Andrew Muncey

Chief Operating Officer and Company Secretary
Simon Boulton

Simon Boulton

Vice President of Scientific Strategy
Show more

Artios Pharma Office Locations

Artios Pharma has an office in Cambridgeshire
Show all (1)

Artios Pharma Financials and Metrics

Summary Metrics

Founding Date

2016

Artios Pharma total Funding

$116.1 m

Artios Pharma latest funding size

$83.61 m

Time since last funding

4 years ago

Artios Pharma investors

Artios Pharma's latest funding round in August 2018 was reported to be $83.6 m. In total, Artios Pharma has raised $116.1 m
Show all financial metrics

Artios Pharma Revenue

GBP

Net income (FY, 2018)

(9.0m)

EBITDA (FY, 2018)

(9.6m)

EBIT (FY, 2018)

(9.8m)

Cash (31-Dec-2018)

38.6m
GBPFY, 2016FY, 2017FY, 2018

EBITDA

(2.9m)(5.7m)(9.6m)

EBIT

(2.9m)(5.7m)(9.8m)

Pre tax profit

(2.9m)(6.0m)(10.9m)

Income tax expense

490.0k1.1m1.9m
GBPFY, 2016FY, 2017FY, 2018

Cash

6.5m11.5m38.6m

Current Assets

7.4m12.8m40.9m

PP&E

1.0k184.0k552.0k

Total Assets

7.4m13.0m41.5m
GBPFY, 2016FY, 2017FY, 2018

Net Income

(2.4m)(4.9m)(9.0m)
GBPFY, 2016

Financial Leverage

1.5 x
Show all financial metrics

Artios Pharma Cybersecurity Score

Cybersecurity ratingPremium dataset

A

90/100

SecurityScorecard logo

Artios Pharma Online and Social Media Presence

Embed Graph

Artios Pharma News and Updates

Artios Pharma Publishes Preclinical Data on The First Selective Small Molecule Polθ Polymerase Inhibitor in Nature Communications

CAMBRIDGE, United Kingdom and NEW YORK, June 17, 2021 (GLOBE NEWSWIRE) -- Artios Pharma Limited (Artios), a leading DNA Damage Response (DDR) company exploiting a broad DDR-based platform and small molecule drug design capabilities to develop a diverse pipeline of product candidates for the treatm…

Artios Pharma Expands US Leadership Team with the Appointment of Abid Ansari as Chief Financial Officer

CAMBRIDGE, England and NEW YORK, Jan. 12, 2021 /PRNewswire/ -- Artios Pharma Limited ("Artios"), a leading DNA Damage Response (DDR) company developing a broad pipeline of precision medicines for the treatment of cancer, announces the appointment of Abid Ansari as Chief Financial Officer...

Artios Pharma, MD Anderson and ShangPharma Announce In-Licensing Agreement for DNA Damage Response Inhibitor

CAMBRIDGE, England and HOUSTON and SOUTH SAN FRANCISCO, Calif., Nov. 6, 2019 /PRNewswire/ -- Artios Pharma Limited (Artios), The University of Texas MD Anderson Cancer Center (MD Anderson) and ShangPharma Innovation (ShangPharma) today announce the in-licensing by Artios of a...

Artios Pharma Appoints Tania Dimitrova as Chief Business Officer and Expands Presence in the United States

CAMBRIDGE, England and NEW YORK, Sept. 24, 2019 /PRNewswire/ -- Artios Pharma Limited (Artios), a leading DNA Damage Response (DDR) company developing a broad pipeline of innovative treatments for cancer, today announces the appointment of Tania Dimitrova as Chief Business Officer and its...

Artios Pharma Announces Appointment of Dr. Ian Smith as Chief Medical Officer

CAMBRIDGE, England, April 1, 2019 /PRNewswire/ -- Artios Pharma Limited (Artios), a leading DNA Damage Response (DDR) company developing a broad pipeline of innovative treatments for cancer, today announces the appointment of Ian Smith, M.D., as Chief Medical Officer. Dr. Smith will...

Artios Pharma Announces Appointment of Professor Rajesh Chopra as Non-Executive Director

CAMBRIDGE, England, Feb. 11, 2019 /PRNewswire/ -- Artios Pharma Limited (Artios), a leading DNA Damage Response (DDR) company developing a broad pipeline of innovative treatments for cancer, today announced the appointment of Professor Rajesh Chopra as Non-Executive Director (NED). In an...
Show more

Artios Pharma Blogs

Artios attending the AACR in New Orleans 8-12 April 2022

Artios will be attending the AACR in New Orleans from 8 – 12 April. If you wish to meet with the team, please contact Stacy at SKnoop@Artios.com Attending will be Niall Martin, (CEO), Abid Ansari (CFO), Tania Dimitrova (CBO) Graeme Smith (CSO) and Jay Majithiya (SP Scientist).

Graeme Smith, CSO and Helen Robinson, VP Biology attending the 5th Digital DDR, ATR, & PARP Summit – 25/26 January 2022

Join Graeme Smith our CSO and Helen Robinson, VP of Biology during the 5th Digital DDR, ATR & PARP Inhibitors Summit from January 25-27. The summit will highlight the new and novel next-generation DDR therapeutics, biomarker understanding and optimal treatment combinations for an array of cancer…

Listen to our CEO and CSO talk at the Northland Synthetic Lethality Conference – Nov 17 2021

Listen to our CEO Dr Niall Martin and our CSO, Dr Graeme Smith talking about Synthetic Lethality; they participated on two panel discussions focusing on Synthetic Lethality and 2022 trends and PARP Inhibitors at the Northland Synthetic Lethality Conference – Nov.17th 2021 Click on the link and add y…

More exciting press coverage following $153 Million financing – Series C

Please click on the links for full coverage updates ENDPOINTSNEWS Novartis partner Artios bags mega-round to drive clinical work on DNA damage repair factors Fierce Biotech Artios raises $153M to fund DNA damage repair clinical trials Business Leader ARTIOS ANNOUNCES £110M SERIES C FINANCING LED BY …

Artios Announces $153 Million (£110 Million) Series C Financing Led by Omega Funds and TCG X

• Funding propels Artios’ ability to progress beyond synthetic lethality and to continue the exploitation of the full spectrum of oncology vulnerabilities presented by the DNA Damage Response through deployment of Artios’ DDR-based platform and small molecule drug discovery capabilities • Financing …

Exciting press coverage following our Polθ (Pol-theta) press release – Nature Communications

Please click on links to see full press coverage: FierceBiotech   Targeting treatment-resistant BRCA-mutated tumors via the newly discovered POLQ pathway BioWorld   Artios heads to the clinic with first ever POLQ inhibitor trial Pharmatimes   Researchers identify new drug class with potential in BRC…
Show more

Artios Pharma Frequently Asked Questions

  • When was Artios Pharma founded?

    Artios Pharma was founded in 2016.

  • Who are Artios Pharma key executives?

    Artios Pharma's key executives are Niall Martin, Graeme Smith and Ian Smith.

  • Who are Artios Pharma competitors?

    Competitors of Artios Pharma include Alimentomica, DARI Motion and Integra Therapeutics.

  • Where are Artios Pharma offices?

    Artios Pharma has an office in Cambridgeshire.

  • How many offices does Artios Pharma have?

    Artios Pharma has 1 office.